merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>may discourage patients from enrolling in trials of other treatments and slow overall progress</answer>
<question_number>3</question_number>
<answer>no correlation between amyloid plaque removal and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>it raises additional safety concerns, making Kisunla appear riskier</answer>
<question_number>5</question_number>
<answer>higher price justified by ability to discontinue treatment after amyloid clearance, reducing duration and overall cost</answer>
<question_number>6</question_number>
<answer>may discourage patients from participating in other clinical trials</answer>
<question_number>7</question_number>
<answer>monthly dosing and the option to stop after plaque clearance reduce treatment inconvenience</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>participants with intermediate tau levels declined more slowly than those with high levels, suggesting earlier treatment is more effective</answer>